The Company was established in the year 2001 with an objective to provide prompt and reliable services to Pharma sector worldwide and improve the product quality with the help of Technological Innovations and Upgradations. Astron commenced its UK operations in 2004 for Quality Testing and QP Release of finished formulations and API. This facility is now UK-MHRA approved.

The Company has products and technology are sold in over 50 countries, which includes European Union, US, Canada Australia, New Zealand, South Africa, Brazil, Mexico, Middle East & North African countries. 18 ANDAs filed in US and 38 EU CTD dossiers developed till 2007.
The Global turnover registered a growth of 40% in the current financial year with the contribution of European market being 50%.
The company is capable of handling Formulation and Analytical Research of Solid Orals, Injectables, Lyophilised injectables, Topicals, Effervescent tablets, Specialty medicaments like Potent drugs & Oncology products. The company has also acquired expertise in oral NDDS and Controlled Release pellets.

Core Sales Territory: Global Regulated Markets

Core Operation: API Manufacture, Finished Dose Manufacture, Sales and Marketing, Distribution

Number of molecules sold: >150

Company's rating: